DOC GENERICI acquired by TPG

TPG Capital has signed a binding agreement to acquire a majority stake in DOC Generici from ICG and Mérieux Equity Partners. The strategic rationale for the transaction is driven by the continued expansion of the Italian generic drug market and DOC Generici's position as a reference brand for patients and healthcare providers. TPG intends to partner with the existing management team to accelerate the company’s leadership through significant investment in organic growth and external consolidation. This acquisition represents a continuation of the company's successful history as a private equity-backed consolidation platform, following previous ownership cycles under Charterhouse, CVC, and ICG. The entry of TPG is expected to provide the capital and global infrastructure necessary to further diversify the product portfolio and optimize the supply chain, ensuring the long-term delivery of high-quality, low-cost medication within the European regulatory framework.

In the past, the company had already been the subject of several LBOs, notably led by Cvc in 2016 and Icg / Merieux Equity Partners in 2019. These multiple LBO cycles illustrate the strong appeal for this type of asset.